BridgeBio Pharma Inc. (BBIO) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

BridgeBio Pharma Inc. (BBIO)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

35.51

1.78 (5.28%)

At close: Jan 14, 2025, 3:59 PM

35.18

-0.93%

Pre-market Jan 15, 2025, 06:00 AM EST

undefined% (undefined)

Bid	35.11
Market Cap	6.71B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.42
PE Ratio (ttm)	-14.67
Forward PE	n/a
Analyst	Buy

Ask	36
Volume	6,952,812
Avg. Volume (20D)	2,078,803
Open	33.73
Previous Close	33.73
Day's Range	33.55 - 36.17
52-Week Range	21.62 - 41.04
Beta	undefined

About BBIO

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-car...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 27, 2019

Employees 550

Stock Exchange NASDAQ

Ticker Symbol BBIO

Website https://www.bridgebio.com

Analyst Forecast

According to 13 analyst ratings, the average rating for BBIO stock is "Buy." The 12-month stock price forecast is $46.5, which is an increase of 30.95% from the latest price.

Buy 84.62%

Hold 7.69%

Sell 0.00%

Stock Forecasts

Next Earnings Release

BridgeBio Pharma Inc. is scheduled to release its earnings on Feb 20, 2025, before market opens.
Analysts project revenue of $39.31M, reflecting a 2.15K% YoY growth and earnings per share of -1.09, making a 13.54% increase YoY.

Why Price Moved

1 month ago · Source

+16.1%

BridgeBio Pharma shares are trading higher after t... Unlock content with Pro Subscription

2 months ago · Source

-5.74%

BridgeBio Pharma shares are trading lower after the company reported mixed Q3 financial results.

News

20 hours ago · youtube.com

BridgeBio CEO Neil Kumar: Our heart disease drug staves off death and hospitalization

BridgeBio CEO Neil Kumar joins CNBC's 'Power Lunch' to discuss the company's latest drug developments, how the drugs compares to competitors in the space, and more.

1 day ago · zacks.com

Strength Seen in BridgeBio Pharma (BBIO): Can Its 16.0% Jump Turn into More Strength?

BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price inc...

1 day ago · investors.com

BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.

Biotech stocks put up a split showing at JPM, where names like BridgeBio, ARS and Harmony stood out with strong preliminary reports. The post BridgeBio, ARS Pharma, Harmony Bio Shine At JPM.

1 month ago · zacks.com

BridgeBio Stock Up on FDA Approval of Cardiovascular Drug

BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.

1 month ago · benzinga.com

FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market

On Friday, the FDA approved BridgeBio Pharma, Inc.'s BBIO Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM to reduce cardiova...

1 month ago · seekingalpha.com

BridgeBio: Next Chapter Begins After Attruby Approval

BridgeBio announced the FDA approval of Attruby (acoramidis) for the treatment of patients with ATTR-CM. The label looks clean and it includes all the relevant clinical data. Attruby's approval also t...

1 month ago · reuters.com

US FDA approves BridgeBio's drug for rare heart condition

The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said on Friday, making it the first new treatment in a market dominated by Pfizer...

1 month ago · benzinga.com

BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market

On Monday, BridgeBio Pharma, Inc. BBIO presented initial outcomes from the ATTRibute-CM open-label extension (OLE) study of acoramidis in ATTR-CM at the American Heart Association Scientific Sessions...

2 months ago · seekingalpha.com

BridgeBio: 2 Weeks Until Major Drug Approval Catalyst - A Buy, With Caveats

BridgeBio Pharma, Inc.'s acoramidis is awaiting FDA's approval decision for transthyretin amyloidosis, with strong clinical data suggesting a likely approval and potential “blockbuster” status. The PD...

2 months ago · zacks.com

BridgeBio Pharma (BBIO) Reports Q3 Loss, Lags Revenue Estimates

BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $1.03. This compares to loss of $1.08 per share a year ago.

2 months ago · zacks.com

BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

BridgeBio Pharma (BBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.